Search Result

Results for "

non-peptide agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin Receptor (3) Apelin Receptor (APJ) (1) Apoptosis (8) Bacterial (6) Bradykinin Receptor (1) CaSR (3) CCR (3) CDK (2) CGRP Receptor (2) Cholecystokinin Receptor (2) CXCR (2) Cytochrome P450 (2) Endogenous Metabolite (1) ERK (4) GCGR (2) GHSR (3) GLP Receptor (1) Insulin Receptor (1) Isotope-Labeled Compounds (2) Neuropeptide Y Receptor (3) Neurotensin Receptor (2) Opioid Receptor (10) Orexin Receptor (OX Receptor) (2) Oxytocin Receptor (4) PI3K (2) Reference Standards (9) RXFP Receptor (2) Somatostatin Receptor (1) STAT (4) Thrombopoietin Receptor (15) Vasopressin Receptor (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (15) Endocrinology (12) Infection (6) Inflammation/Immunology (8) Metabolic Disease (8) Neurological Disease (27)

By Targets:

Angiotensin Receptor (3)

Apelin Receptor (APJ) (1)

Apoptosis (8)

Bacterial (6)

Bradykinin Receptor (1)

CaSR (3)

CCR (3)

CDK (2)

CGRP Receptor (2)

Cholecystokinin Receptor (2)

CXCR (2)

Cytochrome P450 (2)

Endogenous Metabolite (1)

ERK (4)

GCGR (2)

GHSR (3)

GLP Receptor (1)

Insulin Receptor (1)

Isotope-Labeled Compounds (2)

Neuropeptide Y Receptor (3)

Neurotensin Receptor (2)

Opioid Receptor (10)

Orexin Receptor (OX Receptor) (2)

Oxytocin Receptor (4)

PI3K (2)

Reference Standards (9)

RXFP Receptor (2)

Somatostatin Receptor (1)

STAT (4)

Thrombopoietin Receptor (15)

Vasopressin Receptor (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (15)

Endocrinology (12)

Infection (6)

Inflammation/Immunology (8)

Metabolic Disease (8)

Neurological Disease (27)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15306

Eltrombopag Maximum Cited Publications 24 Publications Verification SB-497115	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-50844

Ibutamoren Mesylate 5 Publications Verification MK-677; MK-0677	GHSR	Endocrinology
Ibutamoren Mesylate (MK-677) is a potent, non-peptide Growth hormone secretagogue receptor (GHSR) agonist. Ibutamoren Mesylate is an orally active growth hormone (GH) secretagogue.

HY-15306A

Eltrombopag Olamine Maximum Cited Publications 24 Publications Verification Eltrombopag diethanolamine salt; SB-497115GR	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-15778

AVE 0991 10+ Cited Publications	Angiotensin Receptor	Cardiovascular Disease Endocrinology
AVE 0991 is a nonpeptide and orally active angiotensin-(1-7) receptor agonist with an IC₅₀ of 21 nM .

HY-124733A

LIT-001	Oxytocin Receptor	Neurological Disease
LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC₅₀=55 nM; K_i=226 nM). LIT-001 improves social interaction in a mouse model of autism .

HY-101202

SNC80 NIH 10815	Opioid Receptor	Neurological Disease
SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a K_i of 1.78 nM and an IC₅₀ of 2.73 nM. SNC80 also selectively activates μ-δ heteromer in HEK293 cells with an EC₅₀ of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .

HY-13463

Avatrombopag 5 Publications Verification AKR-501; E5501; YM477	Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-129658A

TT-OAD2	GCGR	Metabolic Disease
TT-OAD2 is a non-peptide *glucagon-like peptide-1 (GLP-1) receptor* agonist with an EC₅₀ of 5 nM. TT-OAD2 has the potential for diabetes treatment .

HY-15522

WAY-267464 2 Publications Verification	Oxytocin Receptor	Neurological Disease
WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .

HY-10199A

Ibutamoren 5 Publications Verification MK-677 free base; MK-0677 free base	GHSR Insulin Receptor	Neurological Disease Metabolic Disease
Ibutamoren (MK-677 free base; MK-0677 free base) is an orally active non-peptide growth hormone secretagogue receptor agonist. Ibutamoren activates signal cascades by mimicking endogenous ligands, triggers pulsatile release of growth hormone from the pituitary gland, and increases serum levels of IGF-1 and insulin-like growth factor-binding protein 3. Ibutamoren not only increases the frequency of growth hormone pulses in male individuals, but also promotes elevated bone formation markers in female individuals with postmenopausal osteoporosis. The combination of Ibutamoren with Alendronate sodium hydrate (HY-11101) significantly increases bone mineral density at the femoral neck. However, Ibutamoren may cause mild, reversible adverse reactions such as increased appetite, fluid retention, and elevated fasting blood glucose. Ibutamoren has been widely used in studies related to idiopathic growth hormone deficiency, sarcopenia, Alzheimer's disease, and osteoporosis .

HY-103302

SUN B8155	CGRP Receptor	Endocrinology
SUN B8155, a non-peptide agonist of calcitonin (CT) receptor, selectively mimics the biological actions of calcitonin. Calcitonin, a 32-amino acid peptide hormone secreted mainly from the thyroid gland, plays an important role in maintaining bone homeostasis .

HY-125976

ML233	Apelin Receptor (APJ)	Cardiovascular Disease
ML233 is a non-peptide based potent apelin receptor (APJ) agonist (EC₅₀=3.7 μM). ML233 displays >21-fold selective over the closely related angiotensin 1 (AT1) receptor (>79 μM) .

HY-12844

Ro 64-6198 1 Publications Verification	Opioid Receptor	Neurological Disease
Ro 64-6198 is a potent, selective, nonpeptide, high-affinity, high cellular permeability and brain penetration N/OFQ receptor (NOP) agonist with an EC₅₀ value of 25.6 nM. Ro 64-6198 is at least 100 times more selective for the NOP receptor over the classic opioid receptors. Ro 64-6198 can be used for stress and anxiety, addiction, neuropathic pain, cough, and anorexia .

HY-122620

Rafutrombopag (tautomerism) Hetrombopag (tautomerism); SHR-8735 (tautomerism)	Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK	Cardiovascular Disease Inflammation/Immunology
Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .

HY-13463A

Avatrombopag maleate 5 Publications Verification AKR-501 maleate; E5501 maleate; YM477 maleate	Thrombopoietin Receptor Cytochrome P450 ERK STAT	Inflammation/Immunology Cancer
Avatrombopag (AKR-501) maleate is an orally active, non-peptide thrombopoietin receptor (TPO receptor) agonist (EC₅₀: 3.3 nM). Avatrombopag maleate mimics the biological activity of TPO. Avatrombopag maleate increases platelet production by activating intracellular signaling systems and promotes the production of platelets and megakaryocytes from hematopoietic precursor cells. Avatrombopag maleate is a substrate for cytochrome P450 (CYP) 2C9 and CYP3A .

HY-109106A

Upacicalcet sodium SK-1403; AJT240; PLS240	CaSR	Endocrinology
Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca ²⁺ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .

HY-101038A

ZK756326 dihydrochloride 1 Publications Verification	CCR	Endocrinology Cancer
ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8.

HY-11077

SR 146131	Cholecystokinin Receptor	Metabolic Disease Endocrinology
SR 146131 is a potent, orally available, and selective nonpeptide (cholecystokinin 1) receptor agonist.

HY-121885

LMD-009 2 Publications Verification	CCR	Metabolic Disease Endocrinology
LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC₅₀s from 11 to 87 nM .

HY-136181A

YNT-185 1 Publications Verification	Orexin Receptor (OX Receptor)	Neurological Disease
YNT-185 is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC₅₀s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 ameliorates narcolepsy-cataplexy symptoms in mouse models .

HY-136181

YNT-185 dihydrochloride 1 Publications Verification	Orexin Receptor (OX Receptor)	Neurological Disease
YNT-185 dihydrochloride is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC₅₀s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 dihydrochloride ameliorates narcolepsy-cataplexy symptoms in mouse models .

HY-108679

WAY-267464 hydrochloride 2 Publications Verification	Oxytocin Receptor	Neurological Disease
WAY-267464 (hydrochloride) is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 (hydrochloride) can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 (hydrochloride) can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .

HY-145589

Rafutrombopag Hetrombopag; SHR-8735	Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK	Cardiovascular Disease Inflammation/Immunology Cancer
Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .

HY-110269

VUF 11222	CXCR	Inflammation/Immunology
VUF 11222 (Compound 38) is a CXCR3 non-peptide-like agonist. VUF 11222 can be used in the study of inflammation .

HY-116567

OPC-51803	Vasopressin Receptor	Metabolic Disease
OPC-51803 is an orally active nonpeptide vasopressin V₂ receptor agonist. OPC-51803 can be used for the research of micturition disorders that result in frequent micturition, such as that from polyuria, nocturnal polyuria, and some kinds of urinary incontinence .

HY-15778A

AVE 0991 sodium salt 10+ Cited Publications	Angiotensin Receptor	Cardiovascular Disease Endocrinology
AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [ ¹²⁵I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC₅₀ of 21 nM .

HY-112824

L-162313	Angiotensin Receptor	Cardiovascular Disease
L-162313 is a non-peptide angiotensin II AT1 and AT2 receptor agonist, with IC₅₀ values of 1.1 and 2.0 nM for AT1 and AT2 receptor, respectively. L-162313 can be used for the research of vasoconstriction, aldosterone release, and cardiovascular growth .

HY-145278

RXFP3/4 agonist 2	RXFP Receptor	Neurological Disease
RXFP3/4 agonist 2 is a potent, nonpeptide dual RXFP3/4 agonist (EC₅₀=3.1 and 2.7 nM). RXFP3/4 agonist 2 also potently promotes interactions between RXFP3 and β-arrestin-2 with EC₅₀ values in the range of 10-22 nM .

HY-103536

Galnon	Neuropeptide Y Receptor	Neurological Disease
Galnon is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with K_is of 11.7 and 34.1 μM respectively. Galnon exhibits anticonvulsant and anxiolytic effects .

HY-129658

TT-OAD2 free base	GCGR	Metabolic Disease
TT-OAD2 free base is a non-peptide *glucagon-like peptide-1 (GLP-1) receptor* agonist with an EC₅₀ of 5 nM. TT-OAD2 free base has the potential for diabetes treatment .

HY-15306S

Eltrombopag-13C4 1 Publications Verification SB-497115-¹³C₄	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-105235

Enadoline CI-977	Opioid Receptor	Neurological Disease
Enadoline (CI-977) is a highly selective, brain-penetrating, and nonpeptide kappa-opioid receptor (KOR) agonist (K_i=1.25 nM). Antinociceptive effects .

HY-13463B

Avatrombopag hydrochloride 5 Publications Verification AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride	Thrombopoietin Receptor	Cardiovascular Disease Cancer
Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-103536A

Galnon TFA	Neuropeptide Y Receptor	Neurological Disease
Galnon TFA is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with K_is of 11.7 and 34.1 μM respectively. Galnon TFA exhibits anticonvulsant and anxiolytic effects .

HY-109106

Upacicalcet SK-1403 free acid; AJT240 free acid; PLS240 free acid	CaSR	Endocrinology
Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .

HY-101038

ZK 756326	CCR	Endocrinology Cancer
ZK756326 is a nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8.

HY-108501

(1R,1'S,3'R/1R,1'R,3'S)-L-054,264	Somatostatin Receptor	Neurological Disease
(1R,1'S,3'R/1R,1'R,3'S)-L-054,264 is a selective non-peptide human somatostatin receptor subtype 2 (sst₂) agonist. (1R,1'S,3'R/1R,1'R,3'S)-L-054,264 can be used in the study of retinal neuromodulation .

HY-124733

LIT-001 free base	Oxytocin Receptor	Neurological Disease
LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC₅₀=55 nM; K_i=226 nM). LIT-001 free base improves social interaction in a mouse model of autism .

HY-137525

NTRC-808	Neurotensin Receptor	Neurological Disease
NTRC-808 is a nonpeptide selective GPCR neurotensin receptor type 2 (NTS2) partial agonist with an EC₅₀ of 14 nM and K_i of 88 nM. NTRC-808 has higher selectivity for NTS2 than for NTS1. NTRC-808 has antipsychotic and analgesic activity .

HY-13463BS

Avatrombopag-d8 hydrochloride AKR-501-d8 hydrochloride; E5501-d8 hydrochloride; YM477-d8 hydrochloride	Isotope-Labeled Compounds Thrombopoietin Receptor	Cardiovascular Disease
Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-13463R

Avatrombopag (Standard) AKR-501 (Standard); E5501 (Standard); YM477 (Standard)	Reference Standards Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (Standard) is the analytical standard of Avatrombopag. This product is intended for research and analytical applications. Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-15306R

Eltrombopag (Standard) SB-497115 (Standard)	Reference Standards Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (Standard) is the analytical standard of Eltrombopag. This product is intended for research and analytical applications. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-15306AR

Eltrombopag Olamine (Standard) Eltrombopag diethanolamine salt (Standard); SB-497115GR (Standard)	Reference Standards Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (Olamine) (Standard) is the analytical standard of Eltrombopag (Olamine). This product is intended for research and analytical applications. Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-115272

GSK894490A	GHSR	Neurological Disease
GSK894490A is a non-peptide ghrelin receptor agonist .

HY-177507

FE101120	Cholecystokinin Receptor	Metabolic Disease
FE101120 is a non-peptide agonist CCK2 receptor agonist. FE101120 can be used for the study of diabetes .

HY-107094

MT-7716 hydrochloride W-212393 hydrochloride	Opioid Receptor	Neurological Disease
MT-7716 hydrochloride (W-212393 hydrochloride) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention .

HY-123376

FR-190997	Bradykinin Receptor	Neurological Disease
FR-190997 is a non-peptide Bradykinin B2 receptor selective agonist, K_i value is 9.8 nM. FR-190997 is also an effective antihypertensive agent .

HY-107094A

MT-7716 free base W-212393	Opioid Receptor	Neurological Disease
MT-7716 free base (W-212393) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention .

HY-12698

NNC 63-0532	Opioid Receptor	Neurological Disease
NNC63-0532 is a novel non-peptide nociceptin receptor (ORL1) agonist, with EC₅₀s of 305 nM. NNC63-0532 plays important roles in many disorders such as pain, drug addiction .

HY-118037

VUF10132	CXCR	Inflammation/Immunology
VUF10132 is a non-peptide CXCR3 receptor antagonist with anti-inflammatory activity, inhibiting diseases such as rheumatoid arthritis, multiple sclerosis, and psoriasis. VUF10132 has high affinity for the human CXCR3 receptor but slightly lower affinity for the murine CXCR3 receptor. Additionally, VUF10132 exhibits inverse agonist properties at the CXCR3 receptor .

Cat. No.	Product Name	Chemical Structure

HY-15306S

Eltrombopag-13C4

1 Publications Verification

Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-13463BS

Avatrombopag-d8 hydrochloride

Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-W713365

Eltrombopag-d3

Eltrombopag-d₃ (SB-497115-d₃) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: